LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Aandelen Lijst・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-0.05% downside

Nieuwssentiment

By Acuity

14%

86%

11 / 374 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 dec 2025, 16:42 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

12 dec 2025, 23:49 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dec 2025, 22:52 UTC

Marktinformatie

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dec 2025, 22:32 UTC

Winsten

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 20:45 UTC

Winsten

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dec 2025, 20:41 UTC

Marktinformatie

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dec 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dec 2025, 19:23 UTC

Winsten

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dec 2025, 18:35 UTC

Acquisities, Fusies, Overnames

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dec 2025, 18:33 UTC

Acquisities, Fusies, Overnames

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dec 2025, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dec 2025, 17:49 UTC

Winsten

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dec 2025, 17:34 UTC

Acquisities, Fusies, Overnames

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12 dec 2025, 17:33 UTC

Acquisities, Fusies, Overnames

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12 dec 2025, 17:33 UTC

Acquisities, Fusies, Overnames

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12 dec 2025, 17:32 UTC

Acquisities, Fusies, Overnames

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12 dec 2025, 17:31 UTC

Acquisities, Fusies, Overnames

Orange to Buy the Stake for EU4.25B in Cash

12 dec 2025, 17:24 UTC

Marktinformatie

Argentina Predicts Record Wheat Crop -- Market Talk

12 dec 2025, 17:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

12 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 17:18 UTC

Marktinformatie

Winsten

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12 dec 2025, 17:09 UTC

Marktinformatie

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12 dec 2025, 17:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 dec 2025, 16:47 UTC

Marktinformatie

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12 dec 2025, 16:39 UTC

Marktinformatie

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

12 dec 2025, 16:27 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

12 dec 2025, 16:15 UTC

Winsten

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

12 dec 2025, 15:35 UTC

Winsten

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dec 2025, 14:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Mirati Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

11 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.